Form 4: Tango Therapeutics R&D President Boosts Equity Holdings

Adam Crystal, President of R&D at Tango Therapeutics, acquired new restricted stock units and stock options while selling shares to cover tax obligations.

Summary

• Adam Crystal, President, R&D of Tango Therapeutics, Inc. (TNGX), acquired 47,460 restricted stock units (RSUs) on February 2, 2026, which will vest over three years starting February 1, 2027.
• Crystal also received a grant of 284,760 stock options on February 2, 2026, with an exercise price of $11.94, vesting over four years starting January 1, 2027, and expiring on February 2, 2036.
• To cover tax withholding obligations related to RSU vesting, Crystal sold a total of 18,452 shares of common stock on February 3, 2026.
• The sales included 18,251 shares at a weighted average price of $12.2573 per share (ranging from $11.88 to $12.875) and 201 shares at a weighted average price of $12.8971 per share (ranging from $12.88 to $12.91).
• Following these transactions, Crystal directly beneficially owns 187,218 shares of common stock and 284,760 derivative securities (stock options).

Sentiment

Score: 7

Explanation: StockSavvy.ai views this filing positively as it reflects a significant increase in a key R&D executive's long-term equity alignment with Tango Therapeutics, which is a strong indicator of continued commitment and incentive for future performance. The sales were non-discretionary tax-related, mitigating any negative interpretation.

Positives

• Adam Crystal, a key executive, significantly increased his potential equity stake in Tango Therapeutics through the acquisition of 47,460 restricted stock units and a grant of 284,760 stock options, aligning his interests with long-term shareholder value.
• The vesting schedules for both RSUs and stock options extend over multiple years, indicating a commitment to the company's sustained performance and Crystal's continued service.

Negatives

• The reported sales of 18,452 shares of common stock were solely for tax withholding obligations under a 'sell-to-cover' policy and were automatic, not discretionary, thus not indicating a negative sentiment from management regarding the company's prospects.

Future Outlook

The vesting schedules for the newly acquired restricted stock units and stock options extend through early 2029 and 2036, respectively, contingent on Adam Crystal's continuous service, indicating a long-term incentive structure for a key R&D executive.

Industry Context

StockSavvy.ai notes that insider transactions, particularly grants of equity compensation like RSUs and stock options, are common in the biotechnology and pharmaceutical sectors. These grants serve to align executive incentives with long-term company performance and shareholder interests, which is a standard practice for retaining key talent in a competitive industry like drug development. The 'sell-to-cover' tax sales are also a routine occurrence and generally not indicative of a change in management's outlook on the company's prospects.

Comparison to Industry Standards

• The structure of equity compensation, including multi-year vesting schedules for RSUs and stock options, is consistent with typical practices observed in publicly traded biotechnology companies of similar size and stage, such as those seen at companies like Relay Therapeutics or Revolution Medicines, which also use long-term equity incentives to retain and motivate R&D leadership.
• The 'sell-to-cover' mechanism for tax obligations is a standard and widely accepted practice across all industries for executive compensation, ensuring compliance with tax laws without requiring executives to use personal funds for immediate tax liabilities upon vesting.

Stakeholder Impact

• Shareholders: The increased equity holdings of a key R&D executive align management's interests with long-term shareholder value, potentially fostering greater commitment to company success.
• Employees: The compensation structure for a senior executive may set a precedent or reflect the company's overall approach to incentivizing key talent.

Next Steps

• The restricted stock units will vest in three tranches on February 1, 2027, February 14, 2028, and February 12, 2029, subject to continuous service.
• The stock options will begin vesting on January 1, 2027, with 25% vesting, and the remainder vesting in 36 equal monthly installments thereafter, subject to continuous service.

Key Dates

Recommendation

This Form 4 filing primarily details routine executive compensation and tax-related share sales, which are expected events and do not provide new fundamental information to warrant a change in investment thesis. The increased equity alignment of a key executive is a positive, but not a catalyst for a 'buy' recommendation on its own. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

Tango Therapeutics, TNGX, Adam Crystal, Form 4, Insider Transaction, Restricted Stock Units, Stock Options, Equity Compensation, Sell-to-Cover, Officer Transaction